Table 2.

Effect of steroid use, DMD genotype, and SPP1 rs11730582 genotype on ambulation loss.

		Dominant model for C			Recessive model for C
		CC/CT	TT		CC	TT/CT
All patients	N	197	129		41	285
	Median age at onset, yr	11.00	10.33		11.17	10.50
	KM ‡Log-Rank p			0.272			0.769
	HR §(95% CI¶)			0.81 (0.64–1.02)			0.95 (0.69–1.32)
	Cox p			0.071			0.774
GCs† treated/truncated DMD	N	85	59		15	129
	Median age at onset, yr	12.00	10.67		12.00	11.50
	KM Log-Rank p			0.006**			0.771
	HR (95% CI)			0.63 (0.45–0.89)			0.93 (0.54–1.58)
	Cox p			0.008**			0.776
GCs untreated/truncated DMD	N	85	52		20	117
	Median age at onset, yr	9.92	9.33		10.00	9.50
	KM Log-Rank p			0.104			0.148
	HR (95% CI)			0.76 (0.53–1.08)			0.72 (0.44–1.15)
	Cox p			0.120			0.169

^†GCs, glucocorticoids.

KM, Kaplan–Meier survival analysis with log-rank comparison of median age at loss of ambulation.

^§HR, hazard ratio for SPP1 genotype in a Cox regression model.

^¶CI, confidence interval.

^**p < 0.01.